Counteracting antibiotic resistance: Breaking barriers among antibacterial strategies

Expert Opinion on Therapeutic Targets

Volumn 18, Issue 8, 2014, Pages 851-861

  Baquero, Fernando ^a   Coque, Teresa M ^a   Cantón, Rafael ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Antibiotic resistance; Antimicrobial drugs; Compartmentalized therapy; Global risks; Integrative therapy; Multi target therapy; Public health

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; DISINFECTANT AGENT; PROBIOTIC AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTISEPSIS; BACTERIOPHAGE; CHEMOTHERAPY; DISINFECTION; ENVIRONMENTAL SANITATION; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INDIVIDUALITY; INFECTION; INFECTION PREVENTION; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT CARE; REVIEW; SYSTEMIC THERAPY; SYSTEMS BIOLOGY; TOPICAL TREATMENT; VACCINATION; WASTE MANAGEMENT; ANIMAL; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; MICROBIOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84904414406     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2014.925881     Document Type: Review

References (108)

1. Mart́nez JL. Natural antibiotic resistance and contamination by antibiotic resistance determinants: The two ages in the evolution of resistance to antimicrobials. Front Microbiol 2012;3:1
2. Gillings MR, Stokes HW. Are humans increasing bacterial evolvability Trends Ecol Evol 2012;27:346-52
3. FCO, Foreign and Commonwealth Office. G8 Science Ministers Statement. 2013. Available from: https://www. google.es/#q=fco+acronym&safe=active
4. World EconomicForum WE. Global Risks 2014 report, Ninth Edition. 2014. Available from: http://www3. weforum.org/docs/WEF-GlobalRisks-Report-2014.pdf
5. Laxminarayan R, Duse A, Wattal C, et al. Antibiotic resistance-the need for global solutions. Lancet Infect Dis 2013;13:1057-98.
6. Centers for Disease Control and Prevention. Threat Report 2013 j Antimicrobial Resistance j CDC. Cent Dis Control Prev Website. 2013. Available from: http://www.cdc.gov/drugresistance/threat-report-2013
7. Baquero F, Garau J. Prudent use of antimicrobial agents: Revisiting concepts and estimating perspectives in a global world. Enferm Infecc Microbiol Clin 2010;28:487-8
8. Geli P, Laxminarayan R, Dunne M, et al. "One-size-fits-all" Optimizing treatment duration for bacterial infections. PLoS One 2012;7:e29838
9. Tam VH, Louie A, Deziel MR, et al. The relationship between quinolone exposures and resistance amplification is characterized by an inverted U: A new paradigm for optimizing pharmacodynamics to counterselect resistance. Antimicrob Agents Chemother 2007;51:744-7 (Pubitemid 46185299)
10. Yeo CL, Wu JE, Chung GW-T, et al. Antimicrobial stewardship auditing of patients reviewed by infectious diseases physicians in a tertiary university hospital. Antimicrob Resist Infect Control 2013;2:29
11. Sepkowitz KA. Finland, Weinstein, and the Birth of Antibiotic Regret-NEJM. N Engl J Med 2012;367:102-3
12. Hopkins AL. Network pharmacology: The next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
13. Csermely P, Korcsmáros T, Kiss HJM, et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery: A comprehensive review. Pharmacol Ther 2013;138:333-408
14. Meyer UA, Zanger UM, Schwab M. Omics and drug response. Annu Rev Pharmacol Toxicol 2013;53:475-502
15. Rubin C, Myers T, Stokes W, et al. Review of institute of medicine and national research council recommendations for one health initiative. Emerg Infect Dis 2013;19:1913-17.
16. Backman C, Taylor G, Sales A, et al. An integrative review of infection prevention and control programs for multidrugresistant organisms in acute care hospitals: A socio-ecological perspective. Am J Infect Control 2011;39:368-78
17. The Antimicrobial Resistance Research Program of the National Institute of Allergy and Infectious Diseases. National Institute of Allergy and Infectious Diseases. 2014. Available from: http://www.niaid.nih.gov/topics/ antimicrobialResistance/Documents/ARstrategicplan2014.pdf
18. Shlaes DM, Sahm D, Opiela C, et al. The FDA reboot of antibiotic development. Antimicrob Agents Chemother 2013;57:4605-7
19. Relman DA. Microbial genomics and infectious diseases. N Engl J Med 2011;365:347-57
20. NIAID Strategic Plan 2013. National Institute of Allergy and Infectious Diseases. 2013. Available from: http://www.niaid.nih.gov/about/whoWeAre/ planningPriorities/Documents/NIAIDStrategicPlan2013.pdf
21. HMA definitions of the terms "Antibiotic" and "Antimicrobial". The Heads of Medicines Agencies website. 2012. Available from: http://www.hma.eu/fileadmin/dateien/Veterinary-medicines/00-HMA- Vet/02-HMA-Task-Force/03-HMA-vet-TF-AMR/2012-11-HMA-agreed-AB-AM-definitions.pdf
22. Food Drug Administration (FDA). Drugs@FDA Glossary of Terms. Drug Approv Databases. 2012. Available from: http://www.fda.gov/Drugs/informationondrugs/ ucm079436
23. Food Drug Administration (FDA). Guidance for Industry Information and Establishment Description Information for a Vaccine. 1999. Available from: http://www.fda.gov/downloads/biologicsbloodvaccines/guidance complianceregulatoryinformation/guidances/vaccines/ucm092272.pdf
24. Ogi C, Aruga A. Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology 2013;2:e26012
25. Na H-N, Kim H, Nam J-H. Prophylactic and therapeutic vaccines for obesity. Clin Exp Vaccine Res 2014;3:37-41
26. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am 2014;98:17-38
27. Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity 2013;39:38-48
28. Jutel M, Van de Veen W, Agache I, et al. Mechanisms of allergen-specific immunotherapy and novel ways for vaccine development. Allergol Int 2013;62:425-33
29. Adams LG, Khare S, Lawhon SD, et al. Enhancing the role of veterinary vaccines reducing zoonotic diseases of humans: Linking systems biology with vaccine development. Vaccine 2011;29:7197-206
30. Guidance Document: Disinfectant Drugs 1994. Government of Canada, Health Canada, Health Products and Food Branch, Therapeutic Products Directorate B of GI and VD. Available from: http://www.jptcp.com/files/draft-disinf-ebauche-de
31. Block SS. editors. WKH. Disinfection, sterilization, and preservation. Lippincott Williams & Wilkins, Philadelphia; 2001
32. Elsmore R. Biocide regulation in the EU-past, present and future. Chim OGGI Chem Today 2012;30:58-60
33. Forsberg KJ, Reyes A, Wang B, et al. The shared antibiotic resistome of soil bacteria and human pathogens. Science 2012;337:1107-11
34. Finley RL, Collignon P, Larsson DGJ, et al. The scourge of antibiotic resistance: The important role of the environment. Clin Infect Dis 2013;57:704-10
35. Forslund K, Sunagawa S, Kultima JR, et al. Country-specific antibiotic use practices impact the human gut resistome. Genome Res 2013;23:1163-9
36. Wellington EMH, Boxall AB, Cross P, et al. The role of the natural environment in the emergence of antibiotic resistance in gram-negative bacteria. Lancet Infect Dis 2013;13:155-65
37. Williams PD, Day T. Epidemiological and evolutionary consequences of targeted vaccination. Mol Ecol 2008;17:485-99 (Pubitemid 350292458)
38. Lutz C, Erken M, Noorian P, et al. Environmental reservoirs and mechanisms of persistence of Vibrio cholerae. Front Microbiol 2013;4:375
39. Chekabab SM, Paquin-Veillette J, Dozois CM, et al. The ecological habitat and transmission of Escherichia coli O157:H7. FEMS Microbiol Lett 2013;341:1-12
40. Borisy AA, Elliott PJ, Hurst NW, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100:7977-82. (Pubitemid 36760080)
41. Keith CT, Borisy AA, Stockwell BR. Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 2005;4:71-8 (Pubitemid 40109591)
42. Aderem A, Adkins JN, Ansong C, et al. A systems biology approach to infectious disease research: Innovating the pathogen-host research paradigm. MBio 2011;2:e00325-10
43. Read AF, Day T, Huijben S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci USA 2011;108(Suppl):10871-7.
44. Huijben S, Bell AS, Sim DG, et al. Aggressive chemotherapy and the selection of drug resistant pathogens. PLoS Pathog 2013;9:e1003578
45. Tamma PD, Cosgrove SE, Maragakis LL. Combination therapy for treatment of infections with gram-negative bacteria. Clin Microbiol Rev 2012;25:450-70
46. Traugott KA, Echevarria K, Maxwell P, et al. Monotherapy or combination therapy The pseudomonas aeruginosa conundrum. Pharmacotherapy 2011;31:598-608
47. Thiem U, Heppner H-J, Pientka L. Elderly patients with communityacquired pneumonia. Drugs Aging 2011;28:519-37
48. Lipsitch M, Levin BR. Population dynamics of tuberculosis treatment: Mathematical models of the roles of non-compliance and bacterial heterogeneity in the evolution of drug resistance. Int Union Against Tuberc Lung Dis 1998;2:187-99 (Pubitemid 28123517)
49. Ankomah P, Johnson PJT, Levin BR. The pharmaco-, population and evolutionary dynamics of multi-drug therapy: Experiments with Staphylococcus aureus and Escherichia coli and computer simulations. PLoS Pathog 2013;9:e1003300
50. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997;94:12106-11. (Pubitemid 27467850)
51. Chait R, Craney A, Kishony R. Antibiotic interactions that select against resistance. Nature 2007;446:668-71 (Pubitemid 46606886)
52. Bergstrom CT, Lo M, Lipsitch M. From The Cover: Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci USA 2004;101:13285-90 (Pubitemid 39209657)
53. Pritchard JR, Bruno PM, Gilbert LA, et al. Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci USA 2013;110:E170-9.
54. Schellekens H, Klinger E, Mühlebach S, et al. The therapeutic equivalence of complex drugs. Regul Toxicol Pharmacol 2011;59:176-83
55. Valverde A, Grill F, Coque TM, et al. High rate of intestinal colonization with extended-spectrum-lactamase-producing organisms in household contacts of infected community patients. J Clin Microbiol 2008;46:2796-9
56. Chitnis AS, Caruthers PS, Rao AK, et al. Outbreak of carbapenem-resistant enterobacteriaceae at a long-term acute care hospital: Sustained reductions in transmission through active surveillance and targeted interventions. Infect Control Hosp Epidemiol 2012;33:984-92
57. Won SY, Munoz-Price LS, Lolans K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011;53:532-40
58. Barnes SL, Harris AD, Golden BL, et al. Contribution of interfacility patient movement to overall methicillin-resistant Staphylococcus aureus prevalence levels. Infect Control Hosp Epidemiol 2011;32:1073-8
59. Wilkinson K, Grant WP, Green LE, et al. Infectious diseases of animals and plants: An interdisciplinary approach. Philos Trans R Soc Lond B Biol Sci 2011;366:1933-42
60. Strachan NJC, Hunter CJ, Jones CDR, et al. The relationship between lay and technical views of Escherichia coli O157 risk. Philos Trans R Soc Lond B Biol Sci 2011;366:1999-2009
61. Remenyi B, Carapetis J, Wyber R, et al. Position statement of the World Heart Federation on the prevention and control of rheumatic heart disease. Nat Rev Cardiol 2013;10:284-92
62. Elias J, Schouls LM, van de Pol I, et al. Vaccine preventability of meningococcal clone, Greater Aachen Region. Germany Emerg Infect Dis 2010;16:465-72
63. Blower SM, Chou T. Modeling the emergence of the "hot zones": Tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004;10:1111-16 (Pubitemid 39424873)
64. Hu VH, Harding-Esch EM, Burton MJ, et al. Epidemiology and control of trachoma: Systematic review. Trop Med Int Health 2010;15:673-91
65. Diez Roux AV, Aiello AE. Multilevel analysis of infectious diseases. J Infect Dis 2005;191(Suppl):S25-33 (Pubitemid 40144226)
66. Baquero F, Mart́nez J-L, Cantón R. Antibiotics and antibiotic resistance in water environments. Curr Opin Biotechnol 2008;19:260-5
67. Ehrlich PR, Mooney HA. Extinction, substitution, and ecosystem services. Bioscience 1983;33:248-54
68. Didelot X, Bowden R, Wilson DJ, et al. Transforming clinical microbiology with bacterial genome sequencing. Nat Rev Genet 2012;13:601.
69. Gardy JL, Johnston JC, Ho Sui SJ, et al. Whole-genome sequencing and socialnetwork analysis of a tuberculosis outbreak. N Engl J Med 2011;364:730-9
70. Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012;4:148ra116
71. Rasko DA, Webster DR, Sahl JW, et al. Origins of the Escherichia strain causing an outbreak of hemolytic-uremic syndrome in Germany. N Engl J Med 2011;365:709-17
72. Didelot X, Nell S, Yang I, et al. Genomic evolution and transmission of Helicobacter pylori in two South African families. Proc Natl Acad Sci USA 2013;110:13880-5
73. Delany I, Rappuoli R, Seib KL. Vaccines, reverse vaccinology, and bacterial pathogenesis. Cold Spring Harb Perspect Med 2013;3:a012476
74. Marti E, Jofre J, Balcazar JL. Prevalence of antibiotic resistance genes and bacterial community composition in a river influenced by a wastewater treatment plant. PLoS One 2013;8:e78906
75. Knapp CW, McCluskey SM, Singh BK, et al. Antibiotic resistance gene abundances correlate with metal and geochemical conditions in archived Scottish soils. PLoS One 2011;6:e27300
76. Seiler C, Berendonk TU. Heavy metal driven co-selection of antibiotic resistance in soil and water bodies impacted by agriculture and aquaculture. Front Microbiol 2012;3:399
77. Fahrenfeld N, Knowlton KF, Krometis L-A, et al. Effect of manure application on abundance of antibiotic resistance genes and their attenuation rates in soil: Field-scale mass balance approach. Environ Sci Technol 2014;48:2643-50
78. Timoney JF, Port J, Giles J, et al. Heavy-metal and antibiotic resistance in the bacterial flora of sediments of New York Bight. Appl Environ Microbiol 1978;36:465-72 (Pubitemid 9029768)
79. Smets BF, Morrow JB, Arango Pinedo C. Plasmid introduction in metal-stressed, subsurface-derived microcosms: Plasmid fate and community response. Appl Environ Microbiol 2003;69:4087-97 (Pubitemid 36870069)
80. Oggioni MR, Furi L, Coelho JR, et al. Recent advances in the potential interconnection between antimicrobial resistance to biocides and antibiotics. Expert Rev Anti Infect Ther 2013;11:363-6.
81. Russell AD. Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. J Appl Microbiol 2002;92(Suppl):121S- 35S (Pubitemid 34535514)
82. Baquero F. Environmental stress and evolvability in microbial systems. Clin Microbiol Infect 2009;15(Suppl 1):5-10
83. Baquero F. On the shifting balance: The case of Staphylococcus aureus CC398. MBio 2012;3:1-2
84. Baquero F. Predictions: Evolutionary trajectories and planet medicine. Microb Biotechnol 2009;2:130-2
85. Daughton CG, Ruhoy IS. Green pharmacy and pharm Ecovigilance: Prescribing and the planet. Expert Rev Clin Pharmacol 2011;4:211-32
86. Fajardo A, Linares JF, Mart́nez JL. Towards an ecological approach to antibiotics and antibiotic resistance genes. Clin Microbiol Infect 2009;15(Suppl 1):14-16
87. Mart́nez JL. Antibiotics and antibiotic resistance genes in natural environments. Science 2008;321:365-7 (Pubitemid 352029941)
88. Smillie CS, Smith MB, Friedman J, et al. Ecology drives a global network of gene exchange connecting the human microbiome. Nature 2011;480:241-4
89. Mart́nez JL. Bottlenecks in the transferability of antibiotic resistance from natural ecosystems to human bacterial pathogens. Front Microbiol 2011;2:265
90. Baquero F, Coque TM, de la Cruz F. Ecology and evolution as targets: The need for novel eco-evo drugs and strategies to fight antibiotic resistance. Antimicrob Agents Chemother 2011;55:3649-60.
91. Olson S, Claiborne AB. Strengthening a workforce for innovative regulatory science in therapeutics development: Workshop summary. National Academies Press, Washington DC; 2012
92. Baquero F. Metagenomic epidemiology: A public health need for the control of antimicrobial resistance. Clin Microbiol Infect 2012;18(Suppl 4):67-73
93. Stecher B, Maier L, Hardt W-D. "Blooming" in the gut: How dysbiosis might contribute to pathogen evolution. Nat Rev Microbiol 2013;11:277-84
94. Price LB, Johnson JR, Aziz M, et al. The epidemic of extended-spectrum- blactamase-producing Escherichia coli st131 is driven by a single highly pathogenic subclone, H30-Rx. MBio 2013;4:e00377-13
95. Backman C, Marck PB, Krogman N, et al. Barriers and bridges to infection prevention and control: Results of a qualitative case study of a Netherlands' surgical unit. BMJ Open 2012;2:e000511
96. Buehlmann M, Frei R, Fenner L, et al. Highly effective regimen for decolonization of methicillin-resistant Staphylococcus aureus carriers. Infect Control Hosp Epidemiol 2008;29:510-16 (Pubitemid 351918029)
97. Daneman N, Sarwar S, Fowler RA, et al. Effect of selective decontamination on antimicrobial resistance in intensive care units: A systematic review and meta-analysis. Lancet Infect Dis 2013;13:328-41
98. Reid G, Younes JA, Van der Mei HC, et al. Microbiota restoration: Natural and supplemented recovery of human microbial communities. Nat Rev Microbiol 2011;9:27-38
99. Handel A, Margolis E, Levin BR. Exploring the role of the immune response in preventing antibiotic resistance. J Theor Biol 2009;256:655-62
100. Tekle YI, Nielsen KM, Liu J, et al. Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains. PLoS One 2012;7:e50688.
101. Dale JB, Fischetti VA, Carapetis JR, et al. Group A streptococcal vaccines: Paving a path for accelerated development. Vaccine 2013;31(Suppl 2):B216-22
102. Youngblood B, Hale JS, Akondy R. Using epigenetics to define vaccineinduced memory T cells. Curr Opin Virol 2013;3:371-6
103. Sánchez-Romero MA, Casades-us J. Contribution of phenotypic heterogeneity to adaptive antibiotic resistance. Proc Natl Acad Sci USA 2014;111:355-60
104. Joice R, Lipsitch M. Targeting imperfect vaccines against drug-resistance determinants: A strategy for countering the rise of drug resistance. PLoS One 2013;8:e68940
105. Finland M, Weinstein L. Complications induced by antimicrobial agents. N Engl J Med 1953;248:220-6
106. Hancock REW. Collateral damage. Nat Biotechnol 2014;32:66-8
107. Omenn GS. Evolution in health and medicine Sackler colloquium: Evolution and public health. Proc Natl Acad Sci USA 2010;107(Suppl):1702-9
108. Woolhouse M. How to make predictions about future infectious disease risks. Philos Trans R Soc Lond B Biol Sci 2011;366:2045-54